A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Breast Cancer
Interventions: DRUG: HD201|DRUG: Herceptin|DRUG: Docetaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: Prestige Biopharma Limited